COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
Black COVID-19 patients were more likely to be hospitalized than white patients in a Centers for Disease Control and Prevention study that looked at cases in metropolitan Atlanta.
The Food and Drug Administration announced a public-private partnership to advance COVID-19 diagnostics.
The Food and Drug Administration issued updated templates for laboratories and manufacturers requesting emergency use authorization for molecular diagnostic tests that screen asymptomatic individuals for SARS-CoV-2 or use pooled samples.
The Food and Drug Administration said chloroquine phosphate and hydroxychloroquine sulfate could reduce remdesivir's antiviral activity.
COVID-19 hospitalizations were six times higher and deaths 12 times more likely for patients with reported underlying health conditions compared with those with none, according to a new Centers for Disease Control and Prevention study.
The Food and Drug Administration last week issued an emergency use authorization for Cue Health Inc.’s new SARS-CoV-2 nasal swab test in patient care settings.
The Centers for Disease Control and Prevention has consolidated its recommendations for COVID-19 testing, which it will update as additional information becomes available.
The Food and Drug Administration said it no longer authorizes the use of hydroxychloroquine or chloroquine as an effective treatment of COVID-19.
The Centers for Disease Control and Prevention released guidance on using telehealth to expand access to health care services during the COVID-19 pandemic and beyond.
The Food and Drug Administration authorized the first COVID-19 diagnostic test with next generation sequencing, which can generate information about the genomic sequence of the SARS-CoV-2 coronavirus.